Treatment of borderline personality disorder with atypical antipsychotic drugs;Behandlung der borderline-persönlichkeitsstörung mit atypischen antipsychotika

Nervenarzt

Volumn 78, Issue 9, 2007, Pages 1003-1013

  Mobascher, A ^a   Mobascher, J ^a   Schmahl, C ^b   Malevani, J ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

Atypical antipsychotics; Borderline personality disorder; Dialectic behavioural therapy; Pharmacotherapy

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CLOZAPINE; FLUOXETINE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; ZIPRASIDONE;

BEHAVIOR THERAPY; BORDERLINE STATE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG TOLERABILITY; HUMAN; MONOTHERAPY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; CLINICAL TRIALS AS TOPIC; HUMANS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 34548570817     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-006-2243-3     Document Type: Review

References (31)

1. American Psychiatric Association (2001) Practice guidelines for the treatment of patients with borderline personality disorder. Am J Psychiatry 158: 1-52
2. Arntz, A, van den Hoorn, M, Cornelis J et al. (2002) Reliability and validity of the borderline personality disorder severity index. J Personal Disord 17: 45-59
3. Bellino S, Paradiso E, Bogetto F (2006) Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study. J Clin Psychiatry 67: 1042-1046
4. Benedetti F, Sforzini l, Colombo C J et al. (1998) Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychitry 59: 103-107
5. Bogenschutz MP, George NH (2004) Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 65: 104-109
6. Bohus M, Limberger MF, Frank U J et al. (2001) Entwicklung der Borderline-Symptom-Liste. Psychother Psychosom Med Psychol 51: 201-211
7. Chengappa KN, Ebeling T, Kang JS J et al. (1999) Clozapine reduces severe self mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry 60: 477-484
8. Frankenburg FR, Zanarini MC (1993) Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 34: 402-405
9. Giesen-Bloo J, van Dyck R, Spinhoven P J et al. (2006) Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Arch Gen Psychiatry 63: 649-658
10. Grootens KP, Verkes RJ (2005) Emerging evidence for the use of atypical antipsychotics in borderline personality disorder. Pharmacopsychiatry 38: 20-23
11. Hilger E, Barnas C, Kasper S (2003) Quetiapine in the treatment of borderline personality disorder. World J Biol Psychiatry 4: 42-44
12. Lieb K, Zanarini MC, Schmahl C et al. (2004) Borderline personality disorder. Lancet 364: 453-461
13. Linehan MM, Armstrong HE, Suarez A et al. (1991) Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Arch Gen Psychiatry 48:1060-1064
14. Linehan M (1996) Dialektisch-behaviorale Therapie bei Borderline- Persönlichkeitsstörung CIP Medien München
15. Linehan M, Comtois KA, Murray AM J et al. (2006) Two-year randomized controlled trial and dollow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry 63: 757-766
16. Mobascher A, Mobascher J, Schlemper V et al. (2006) Aripiprazole pharmacotherapy of borderline personality disorder - a series of 3 consecutive cases. Pharmacopsychiatry 39: 111-112
17. Nickel MK, Muehlbacher M, Nickel C J et al. (2006) Aripiprazole in the treatment of patients with borderline personality disorder: a double blind. placebo-controlled trial. Am J Psychiatry 163: 833-838
18. Pascual JC, Oller S, Soler J J et al. (2004) Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services. J Clin Psychiatry 65: 1281-1283
19. Rinne T, van den Brink W, Wouters L, van Dyck R (2002) SSRI treatment of borderline personality disorder: a randomized placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 159: 2048-2054
20. Rocca P, Marchiaro L, Cocuzza E, Bogetto F (2002) Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 63: 241-244
21. Schmahl C, Bohus M (2001) Symptomorientierte Pharmakotherapie bei Borderline-Persönlichkeitsstörung. Fortschritte Neurologie Psychiatrie 69: 310-321
22. Schulz SC, Camlin KL, Berry SA, Jesberger JA (1999) Olanzapine safety and efficiacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 46: 1429-1435
23. Simpson EB, Yen S, Costello E J et al. (2004) Combined dialectic behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry 65: 379-385
24. Soler J, Pasqual JC, Campins J J et al. (2005) Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 162:1221-1224
25. Tritt K, Nickel C, Lahmann C J et al. (2005) Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 19: 287-291
26. Villeneuve E, Lemelin S (2005) Open-Label Study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: Impulsivity as main target. J Clin Psychiatry 66: 1298-1303
27. Zanarini MC, Frankenburg, FR (2001) Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 62: 849-54
28. Zanarini MC (2003) Zanarini Rating Scale for borderline personality disorder (ZAN-BPD): A continuous measure of DSM-IV borderline psychopathology. J Personal Disord 17: 233-242
29. Zanarini, MC, Frankenburg FR, Hennen J, Silk KR (2003) The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. Am J Psychiatry 160: 274-283
30. Zanarini MC, Frankenburg FR, Parachini EA (2004) A preliminary, randomized trial of fluoxetine, olanzapine and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 65: 903-907
31. Zanarini MC (2006) A dose comparison of olanzapine in borderline personality disorder: a 12-week placebo-controlled study. European ISSPD (International Society for the Study of Personality Disorders) Congress